2010.02.03
DAIICHI SANKYO INITIATES LARGEST SINGLE, DOUBLE-BLIND,RANDOMIZED, PHASE 3 TRIAL FOR TREATMENT AND PREVENTION OF RECURRENT VENOUS THROMBOEMBOLISM
HTML
PDF
2010.02.01
Daiichi Sankyo Submits a New Drug Application in Japan for CS-8958, a Long-Acting Neuraminidase Inhibitor for the Treatment of Influenza
HTML
PDF
2010.01.29
Revision of Earnings Forecasts
HTML
PDF
2010.01.19
Daiichi Sankyo Contributes to Relief Efforts for Haitian Earthquake Victims
HTML
PDF
2010.01.06
Luitpold Pharmaceuticals Inc. Acquires PharmaForce, Inc., a U.S. Specialty Injectable Pharmaceutical Company
HTML
PDF
2010.01.29
Announcement of Financial Results for 3Q of Fiscal 2009
2009.12.11
Material for 4th R&D Meeting
2009.11.25
Daiichi Sankyo's key R&D information now available on our Website
2009.10.30
Announcement of Financial Results for 2Q of Fiscal 2009
2009.07.31
Announcement of Financial Results for 1Q of Fiscal 2009
2010.02.08
Announcement of Approval Application in Japan for Manufacturing and Marketing of SUN Y7017 (Memantine) for the Treatment of Alzheimer's Type Dementia
HTML
PDF
2010.01.20
Daiichi Sankyo Receives Approval to Manufacture and Market Rezaltas(R) Combination Tablets to Treat Hypertension
HTML
PDF
2009.12.07
Seventh Takamine Memorial Sankyo Prize Announced
HTML
PDF
